Loading…
← CockpitCompetitor Analysis › ACRS Aclaris Therapeutics, Inc.Open in the cockpit ↗

Aclaris Therapeutics, Inc.ACRSCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum laggard 17
Mkt cap
$555M
US dollars, full cap
Free float
75%
of shares outstanding
$/day
$11.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-141.7 pp
WACC 9.9%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$3.50
1D+3.5%
1W-19.4%
1M-7.2%
3M-44.7%
6M-22.7%
YTD+16.3%
1Y+42.9%
ATR %9.1%
Beta0.75
52w lowhigh47.0% off high

What Aclaris Therapeutics does

Employees: 73

Aclaris Therapeutics at a glance

Size Aclaris Therapeutics (ACRS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $555M, the 2594th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.50 on 18 Nov 2026.

Performance Over six months the shares fell 22.7%, against -16.7% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 19 in its peer set.

Growth Revenue fell 59.3% over the last twelve months (peer median +6.4%); the operating margin is -1,412.4% (peer median 6.8%).

Valuation It trades at 69.1× enterprise value to sales against a peer median of 5.0× (2nd most expensive of 19).

Capital Return on invested capital runs 141.7 points below its cost of capital (9.9% WACC).

Short interest Short interest is 7.3% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

7510012521 May 202621 Aug 202618 Nov 2026Peer median 84ACRS 77
Six months, rebased to 100: Aclaris Therapeutics against the median of its 20 peers (local-currency closes).

Aclaris Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$6.40M$7.83M$18.7M$31.2M$29.8M
Revenue growth—-58%-40%+5%—
Gross profit$370,000$542,000$3.46M$13.2M$17.8M
EBITDA-$90.0M-$73.4M-$49.0M-$114M-$84.4M
Net income-$79.6M-$64.9M-$132M-$88.5M-$86.9M
Free cash flow-$75.3M-$47.2M-$20.2M-$79.6M-$68.2M
Capital expenditure-$725,000$111,000$35.9M$1.31M$605,000
Total debt$1.71M$2.12M$2.60M$3.50M$2.25M

Quarterly statements and history in the cockpit →

Aclaris Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-20%0%003850002393ZVRA4559002688600568688356ENTXMOREPENLABALMSSENORES361322562157SUPRIYAACRS6-month return →1-month return →
Up and to the right = strong over both horizons. Aclaris Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×50×100×003850002393ZVRA600568688356MOREPENLABALMS3613225647432157SUPRIYAEVONILEACRSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Aclaris Therapeutics is the large dot.

Aclaris Therapeutics competitors and peer comparison

How Aclaris Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Aclaris Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureACRSPeer medianRank in peer set
1-month return-7.2%-11.4%8th highest of 20
6-month return-22.7%-16.7%8th lowest of 19
Distance from 52-week high-47.0%-41.3%5th lowest of 20
Revenue growth (TTM)-59.3%+6.4%4th lowest of 20
Operating margin-1,412.4%6.8%2nd lowest of 19
EV / Sales69.1×5.0×2nd most expensive of 19
ROIC minus cost of capital-141.7 pp-2.5 pplowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%69.1×n/an/a
Boryung 003850.KSSouth Korea$554M-13%+6%6%0.9×-3.1%+12.6%
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%1.2×-5.8%+4.1%
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%2.4×-4.9%+51.6%
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%1.0×-12.3%+11.1%
Jinhe Biotechnology 002688.SZChina$550M-19%+7%5%1.8×1.0%+9.7%
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%6.2×n/an/a
Jenkem Technology 688356.SSChina$563M-30%+52%11%8.7×36.4%+11.2%
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Morepen Laboratories MOREPENLAB.NSIndia$542M+121%+30%11%2.2×n/an/a
Alumis ALMSUnited States$569M-80%-67%-5,375%23.9×n/an/a
Senores Pharmaceuticals SENORES.NSIndia$538M+3%+40%24%7.4×n/an/a
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%1.9×-15.4%+2.8%
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%20.1×n/an/a
Chimin Health Management 603222.SSChina$533M-31%+1%-28%6.6×n/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%101.5×n/an/a
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%4.5×n/an/a
Electra Therapeutics ETRAUnited States$530Mn/an/an/an/an/an/a
Jinling Pharmaceutical 000919.SZChina$529M-15%-8%1%0.7×2.4%+5.0%
Supriya Lifescience SUPRIYA.NSIndia$529M-15%+23%26%5.5×28.2%+15.8%
Evonile Pharma EVONILE.NSIndia$529Mn/a-5%12%16.2×49.3%-1.5%

Questions

Which companies are Aclaris Therapeutics's closest peers?
The cockpit's peer set: Boryung (003850.KS), Tianjin Lisheng Pharmaceutical (002393.SZ), Zevra Therapeutics (ZVRA), Zeria Pharmaceutical (4559.T), Jinhe Biotechnology (002688.SZ), Zhong Zhu Healthcare (600568.SS), Jenkem Technology (688356.SS), Entera Bio (ENTX).
Is Aclaris Therapeutics expensive compared with its peers?
On ev / sales it trades at 69.1× against a peer median of 5.0×, 2nd most expensive of 19 in its peer set.
How has Aclaris Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -22.7% against -16.7% for the median peer; over one year +42.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.